Starlix

RSS

nateglinide

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Starlix has been withdrawn at the request of the marketing-authorisation holder.

This EPAR was last updated on 28/06/2022

Authorisation details

Product details
Name
Starlix
Agency product number
EMEA/H/C/000335
Active substance
nateglinide
International non-proprietary name (INN) or common name
nateglinide
Therapeutic area (MeSH)
Diabetes Mellitus, Type 2
Anatomical therapeutic chemical (ATC) code
A10BX03
Publication details
Marketing-authorisation holder
Novartis Europharm Limited
Revision
15
Date of issue of marketing authorisation valid throughout the European Union
03/04/2001
Contact address

Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland

Product information

08/11/2021 Starlix - EMEA/H/C/000335 - IB/0040

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

Nateglinide is indicated for combination therapy with metformin in type-2 diabetic patients inadequately controlled despite a maximally tolerated dose of metformin alone.

Assessment history

How useful was this page?

Add your rating